Paroxetine, which targets a receptor in the GPCR household, eventually reduced tumor growth in youth sarcoma cells by significantly reducing the number of IGF1R receptors on malignant cells.
Scientists from Karolinska Institute in Sweden and MD Anderson Cancer Center in Houston found the insulin-like development element receptor, also referred to as IGF1R, a receptor that plays a key role in numerous cancers, shares characteristics with G protein-coupled receptors, also known as GCPRs, which are the receptors targeted by numerous existing drugs utilized to treat conditions like allergies, anxiety and stress and anxiety. The commonalities between the 2 groups of receptors showed that drugs used to target GPCRs might also be able to impact the function of the IGF1R..
” Although this study was carried out in mice and we do not yet know how translatable the results are to humans, it provides us hope for repurposing common drugs for young cancer clients desperately requiring much better treatment options,” Caitrín Crudden, PhD, research study author and former PhD student in Karolinska Institutes department of oncology-pathology, said in a news release..
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by clicking here.
Erica Carbajal –
Friday, November 6th, 2020
More posts on oncology: Cancer death danger rises about 10% for every single month of delayed care, study findsMore than 13 percent of cancer-related mutations are acquired, research study finds4 recent cancer care partnerships.
The antidepressant drug paroxetine led to a substantial decrease in childhood sarcoma tumor development after being utilized to deal with cancer cells in a mouse model study, according to research released Nov. 6 in Cancer Research..